340B Rebate Pilot Threatens Hospital Cash Flow in 2027

The 340B Drug Pricing Program is high on the list of financial and policy issues hospital CEOs are tracking, as legal challenges and a coming federal pilot threaten to change how hospitals capture drug discounts, according to Becker's Hospital Review.

Today, eligible hospitals receive 340B discounts up front when they purchase drugs. A limited federal rebate pilot scheduled to take effect Jan. 1, 2027 would flip that model, requiring hospitals to buy drugs at full price and then wait for rebates. That timing gap matters. Instead of an immediate discount, hospitals would front large sums and rely on manufacturers and processes to return the money, tying up working capital that many systems already run thin.

CEOs told Becker's the shift could squeeze cash on hand and, in turn, pressure staffing and other spending that 340B savings help fund. For hospitals that lean on the program to support care for low-income patients, the operational and budgeting stakes are significant well before 2027 arrives.